Document is current

Article History

Received: 20 December 2024

Accepted: 31 March 2025

First Online: 9 May 2025

Declarations

:

: Arianna Tonelli, Diletta Valsecchi, Donatella Vassellatti, Lucia Casoli are employees of Novartis Farma Italy. Marina Venturini has served as an advisory board member and/or consultant and has received fees/speaker’s honoraria and/or has participated in clinical trials for AbbVie, Almirall, Amgen, Bristol Myers Squibb, Boehringer-Ingelheim, Eli Lilly, Galderma, Janssen, Leo Pharma, Novartis, Pierre Fabre, and UCB Pharma. Riccardo Cipelli is an employee of IQVIA Solutions Italy. Anna Balato, Massimiliano Scalvenzi, Caterina Foti, Giovanni Maifredi, Simona Serao Creazzola, Stefania Antonacci, and Alessandra Ori have nothing to disclose.

: The study was approved by the Ethics Committees of all participating Clinical Centers and LHUs, including the Independent Ethics Committee (IEC) of Bari (approval no. 7265, dated 25 January 2023), the Ethics Committee of the University of Campania “Luigi Vanvitelli”—AORN “Ospedale dei Colli” (approval no. 5870/2022, dated 31 March 2022), the Campania Centro Ethics Committee (protocol CE no. 390, dated 28 July 2022), the Ethics Committee of the University of Naples Federico II—AORN A. Cardarelli (approval no. 07/22, dated 21 July 2022), and the Ethics Committee of Brescia (approval no. NP5634, dated 26 January 2023). All subjects provided written informed consent prior to enrollment and consented to the use of their data for publication. All procedures performed were in accordance with the 1964 Helsinki Declaration and its later amendments, Good Clinical Practice, and local applicable regulations.